COPENHAGEN, Denmark, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Vilacto Bio, Inc. the “Company” (OTCQB:VIBI), today announced that it has been made aware of certain promotional activity concerning VIBI common stock.  On November 28, 2017, the Company first became aware of certain promotional activities concerning Vilacto Bio, and its common stock, after receiving notification from OTC Markets that an online promotional report encouraging the purchase of VIBI shares may have had an impact on trading activity in the Company’s securities. Until informed by OTC Markets, the Company was unaware of the promotional activity and remains unaware of the full nature and content of this activity, the extent of the dissemination or the parties involved.  The Company is not affiliated in any way with the authors of the promotional activity identified by OTC Markets.

Certain statements contained in the promotional materials as supplied to the Company by OTC Markets may be materially false and/or misleading.  The Company encourages those interested in the Company to rely solely on information included in its press releases combined with its filings and disclosures made with the U.S. Securities and Exchange Commission.

In its investigation into this matter, the Company has made inquiries of its executive officers, directors and controlling shareholders.  The Company, its officers, directors and controlling shareholders, have not sold or purchased the Company's securities within the past 90 days. Vilacto states definitively that the Company, its officers, directors and, to the Company's knowledge, its controlling shareholders have not, directly or indirectly, authorized or been involved in any way with the creation or distribution of promotional materials of any kind. 

Further, the Company has not, other than disclosed in its periodic reports filed with the Securities and Exchange Commission, issued any shares or convertible instruments allowing conversion to equity securities at prices constituting a discount to the current market rate at the time of the issuance.

About Vilacto Bio, Inc.
Vilacto Bio Inc. (OTCQB:VIBI) is a cosmeceutical and biotech company that has developed the fully patented Lactoactive® molecule, which in numerous studies has demonstrated above average effect in treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels.  The Company also developed and markets a consumer skincare line under the Vilact® trademark.  The Company aims to further develop its Lactoactive® molecule for the purpose of increasing the quality of its retail and medical skin cream products as well as licensing its Lactoactive® molecule to the pharmaceutical industry.  More information about Vilacto can be found on its company website at:     

Vilacto Bio Inc.
Fabriksvej 48
4700 Naestved

Gert Andersen
Phone: +1 646-893-7895     

Forward-Looking Statements & Disclaimers:

The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.